Latham’s life sciences licensing group brings market-leading experience to structuring and negotiating the industry’s most transformative strategic partnerships, joint ventures, and other licensing agreements.
We draw on deep industry experience and technical knowledge to advise life sciences companies and their investors on the full range of technology-based commercial transactions. Many lawyers on our team hold advanced scientific and business degrees, are qualified to practice before the US Patent and Trademark Office, and have held legal and scientific positions within high-profile life sciences companies.
Our team routinely advises on life sciences transactions that receive industry-wide accolades for their innovative approaches to identify, develop and commercialize cutting-edge products. We advise across the spectrum of life sciences transactions, from vendor agreements and intellectual property and technology licensing transactions, to complex strategic alliances and collaborations. We work collaboratively with clients to identify, conceptualize, and develop creative solutions to the thorniest business and legal issues that arise in the course of a complex life sciences transaction.
Financial Times recognizes the firm’s strengths across metrics that assess legal industry leadership and strategic growth.
Amy Hargreaves of Latham & Watkins LLP has helped numerous health care companies reach favorable settlements amid False Claims Act qui tam litigation and federal investigations into things like false billings and insurance fraud, earning her a spot among the health care attorneys honored by Law360 Rising Stars.
With a deep understanding of health care laws and regulations, compliance-related matters, and False Claims Act litigation, Amy Hargreaves assists clients in navigating complex enforcement environments.